CD4<sup>+</sup> T cell-induced inflammatory cell death controls immune-evasive tumours.
Kruse B, Buzzai AC, Shridhar N, Braun AD, Gellert S, Knauth K, Pozniak J, Peters J, Dittmann P, Mengoni M, van der Sluis TC, Höhn S, Antoranz A, Krone A, Fu Y, Yu D, Essand M, Geffers R, Mougiakakos D, Kahlfuß S, Kashkar H, Gaffal E, Bosisio FM, Bechter O, Rambow F, Marine JC, Kastenmüller W, Müller AJ, Tüting T. · 2023
Read CD4<sup>+</sup> T cell-induced inflammatory cell death controls immune-evasive tumours. by Kruse B, Buzzai AC, Shridhar N, Braun AD, Gellert S, Knauth K, Pozniak J, Peters J, Dittmann P, Mengoni M, van der Sluis TC, Höhn S, Antoranz A, Krone A, Fu Y, Yu D, Essand M, Geffers R, Mougiakakos D, Kahlfuß S, Kashkar H, Gaffal E, Bosisio FM, Bechter O, Rambow F, Marine JC, Kastenmüller W, Müller AJ, Tüting T. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10307640.txt.
Introduction
Kruse and a large team report that CD4 T cells can control tumors that evade standard immune attack, through inflammatory cell death, in a 2023 study. Most cancer immunotherapy relies on CD8 killer T cells that spot tumor markers directly. Tumors often escape by losing those markers, which leaves such therapy powerless.
The team shows that helper CD4 T cells can instead trigger a fiery form of death in tumor tissue. That death engulfed even marker-free tumor cells nearby. The finding opens a path to treat tumors that hide from killer T cells.
Catalog record
| CREATOR | Kruse B, Buzzai AC, Shridhar N, Braun AD, Gellert S, Knauth K, Pozniak J, Peters J, Dittmann P, Mengoni M, van der Sluis TC, Höhn S, Antoranz A, Krone A, Fu Y, Yu D, Essand M, Geffers R, Mougiakakos D, Kahlfuß S, Kashkar H, Gaffal E, Bosisio FM, Bechter O, Rambow F, Marine JC, Kastenmüller W, Müller AJ, Tüting T. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 79 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours By Bastian Kruse, Anthony C. Buzzai, Naveen Shridhar, Andreas D. Braun, Susan Gellert, Kristin Knauth, Joanna Pozniak, Johannes Peters, Paulina Dittmann, Miriam Mengoni, Tetje Cornelia van der Sluis, Simon Höhn Published in: Nature DOI: 10.1038/s41586-023-06199-x ABSTRACT Most clinically applied cancer immunotherapies rely on the ability of CD8+ cytolytic T cells to directly recognize and kill tumour cells1–3. These strategies are limited by the emergence of major histocompatibility complex (MHC)-deficient tumour cells and the formation of an immunosuppressive tumour microenvironment4–6. The ability of CD4+ effector cells to contribute to antitumour immunity independently of CD8+ T cells is increasingly recognized, but strategies to unleash their full potential remain to be identified7–10. Here, we describe a mechanism whereby a small number of CD4+ T cells is sufficient to eradicate MHC-deficient tumours that escape direct CD8+ T cell targeting. The CD4+ effector T cells preferentially cluster at tumour invasive margins where they interact with MHC-II+CD11c+ antigen-presenting cells. We show that T helper type 1 cell-directed CD4+ T cells and innate immune stimulation reprogramme the tumour-associated myeloid cell network towards interferon-activated antigen-presenting and iNOS-expressing tumouricidal effector phenotypes. Together, CD4+ T cells and tumouricidal myeloid cells orchestrate the induction of remote inflammatory cell death that indirectly eradicates interferon-unresponsive and MHC-deficient tumours. These results warrant the clinical exploitation of this ability of CD4+ T cells and innate immune stimulators in a strategy to complement the direct cytolytic activity of CD8+ T cells and natural killer cells and advance cancer immunotherapies. MAIN Adoptive cell transfer (ACT) studies using tumour-infiltrating lymphocytes from patients that are expanded ex vivo before their reinfusion provided initial proof-of-principle for the clinical efficacy of T cell immunotherapy11. The recent success of the immune checkpoint blockade (ICB) with monoclonal antibodies targeting the immunoregulatory receptors CTLA4 and PD1 led to the clinical breakthrough of T cell-directed immunotherapies12. The efficacy of ICB is mainly attributed to reactivation of CD8+ T cells that specifically recognize tumour antigens in the form of processed peptide epitopes presented by major histocompatibility complex class I (MHC-I) molecules on tumour cells. Both antigen presentation and MHC expression are upregulated by interferons (IFNs). Following antigen recognition, CD8+ T cells release cytolytic granules and IFNγ that initiate cell death. Despite its clinical efficacy, ICB is limited by the emergence of MHC-deficient and IFN-unresponsive tumour cell clones that escape recognition and destruction by CD8+ cytolytic T cells4,5. There is emerging evidence that CD4+ T cells can also contribute to antitumour immunity, independent of their role as helpers and regulators of CD8+ cytolytic T cells13. A subset of CD4+ T cells develops cytolytic effector functions towards MHC-II-expressing tumour cells14,15. In addition, CD4+ T cells were shown capable of eradicating tumour cells that do not express MHC-II by mobilizing myeloid cells, which are specialized to process and present peptide epitopes on their MHC-II molecules16–18. The therapeutic potential of this indirect CD4+ T cell effector mechanism has, however, remained unclear. Moreover, the spatiotemporal dynamics and the mechanism of action of CD4+ T cells within the tumour tissue have not been fully explained. CLINICAL RELEVANCE OF IMMUNE EVASION Tumour cells can evade recognition and destruction by CD8+ T cells through MHC-I downregulation19. We reassessed the clinical relevance of this immune evasion mechanism in skin metastases of patients with melanoma by immunohistochemistry. Our results show very low MHC-I expression on melanoma cells in seven out of 20 samples that was associated with the absence of tumour-infiltrating CD8+ T cells (Fig. 1a and Extended Data Fig. 1a,b). Expression of MHC-II was mostly restricted to stromal and immune cells at the invasive margins in 15 out of 20 samples, often in association with infiltrating CD8+ T cells. Only two out of 20 samples that were densely infiltrated with CD8+ T cells showed high expression levels of MHC-II on melanoma cells, whereas three out of 20 samples that lacked CD8+ T cell infiltrates barely expressed MHC-II (Fig. 1a and Extended Data Fig. 1c).Fig. 1A small population of CD4+ effector T cells can eradicate MHC-deficient and IFN-unresponsive melanomas that resist destruction by CD8+ cytotoxic T cells.a, Density of CD8+ T cells infiltrating the tumour centre and the invasive margin of 20 human melanoma skin metastases and corresponding MHC-I and MHC-II expression, categorized into high, intermediate (int) and low expression. b, UMAP of single-cell transcriptomes from an extra set of 20 melanoma metastases in skin (n = 5), subcutis (n = 4) and lymph nodes (n = 11) annotated for melanoma, immune and stromal cell phenotypes. c,d, MHC-I (c) and MHC-II (d) gene set expression in single melanoma cells. e, ICB therapy responders in patients with high, intermediate and low MHC-I expression on melanoma cells. f, Structure of recombinant adenovirus Ad-PT. g, Experimental protocol for ACT immunotherapy of established tumours in mice (Cy, C, cyclophosphamide; V, Ad-PT; T, TCRtg Pmel-1 CD8+ or TRP-1 CD4+ T cells; I, innate stimuli, polyI:C and CpG) and time point for flow cytometric analyses. h,i, Kaplan–Meier survival curves of mice bearing established B16 melanomas and treated either with CD4 ACT or CD8 ACT (h) or with the indicated components of the CD4 ACT protocol (i). NT, non-treated; CR, complete responders. i, **P = 0.0084. j,k, Immune cell composition (n = 2 biologically independent samples) (j) and phenotype of endogenous and transferred (VT, CVTI, right columns) CD4+ T cells (k) in tumours treated as indicated (mean ± s.e.m. from n = 4 biologically independent samples). l–o, Graphical representation of the immune cell interaction phenotypes (left) and Kaplan–Meier survival curves (right) of mice bearing established Ciita-KO (l), Trp1-KO (m), CRISPR-ctrl (n) or Jak1-KO (o) melanomas and treated as indicated. o, ****P < 0.0001. p, Immune cell composition of tumours treated as indicated (mean ± s.e.m. from four biologically independent samples). q, Structure of recombinant adenovirus Ad-OVA. r, Graphical representation of the immune cell interaction phenotype of ovalbumin-expressing HCmel12 Jak1-KO cells (left) and Kaplan–Meier survival curves (right) of mice bearing established melanomas treated as indicated. ****P < 0.0001. Survival was statistically compared using a log-rank Mantel–Cox test. NS, not significant.Source Data We independently analysed the expression of MHC molecules in single-cell RNA-sequencing (scRNA-seq) data obtained from a different cohort of 20 patients with treatment-naïve melanoma metastases (Fig. 1b–e)20. Transcriptional MHC-I downregulation in melanoma cells was evident in four out of 20 samples (Fig. 1c and Extended Data Fig. 1d). MHC-II expression was largely absent in melanoma cells and restricted to antigen-presenting immune cells (Fig. 1d and Extended Data Fig. 1e–g). Transcriptional downregulation of MHC-I on melanoma cells was associated with poor response to ICB (Fig. 1e). In aggregate, these results indicate that MHC-I downregulation in tumour cells is a frequent phenomenon during tumour evolution that favours immune escape. ESTABLISHMENT OF A CD4 ACT MODEL To experimentally investigate how CD4+ T cell effector functions could be therapeutically directed against MHC-deficient tumours that evade CD8+ T cell immunity, we used enhanced green fluorescent protein (eGFP+) TRP-1 CD4+ TCRtg T cells and Venus+ Pmel-1 CD8+ TCRtg T cells for ACT immunotherapies21,22. Vaccination with the recombinant adenovirus Ad-PT encoding a Pmel/gp100-TRP-1 fusion protein capable of stimulating both CD4+ and CD8+ TCRtg T cells (Fig. 1f) allowed us to directly compare their antitumour efficacy and their mechanism of action under